Group II mGluR Modulators for TRN Dysfunction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neurodevelopmental disorders, psychiatric disorders, and sleep disorders are inadequate in addressing thalamic reticular nucleus (TRN) dysfunction, which is implicated in conditions such as autism spectrum disorder, attention-deficit hyperactivity disorder, and schizophrenia, and there is a need for effective therapeutic strategies to rescue behavioral deficits associated with TRN dysfunction.

Innovation Solution

Administering an effective amount of a group II metabotropic glutamate receptor modulator, specifically mGluR2/3 agonists like LY354740 or MGS0028, to subjects with TRN dysfunction or those having a loss-of-function mutation in the PTCHD1 gene, to modulate TRN activity and improve behavioral and sleep-related symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for neurodevelopmental disorders are used, then existing therapeutic approaches are maintained, but they are inadequate in addressing thalamic reticular nucleus (TRN) dysfunction

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidability to address TRN dysfunction

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the pharmacological parameter by introducing group II metabotropic glutamate receptor modulators (specifically mGluR2/3 agonists) to alter TRN neuron activity. This parameter change directly addresses TRN dysfunction by enhancing rebound bursting, thereby improving treatment effectiveness for neurodevelopmental disorders while maintaining adaptability to specific pathological mechanisms.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If group II metabotropic glutamate receptor modulators are administered, then behavioral deficits are rescued and TRN neuron activity is enhanced, but this represents a novel therapeutic approach requiring validation

Engineering Contradiction:

Improverescue of behavioral deficitsVSAvoidimplementation of novel therapy

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent performs preliminary validation by demonstrating in mouse models that group II metabotropic glutamate receptor modulators enhance TRN neuron rebound bursting and rescue behavioral deficits. This preliminary action in animal models provides proof of concept and reduces the risk before clinical implementation, making the novel therapeutic approach more viable.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20220313650A1Methods for treating neurodevelopmental disorders

Publication Date: 2022.10.06 THE BROAD INST INC

AI summary

Provided herein are methods for treating a neurodevelopmental disorder using a group II metabotropic glutamate receptor modulator.